Acorda Therapeutics sold non-US rights to its multiple sclerosis (MS) drug, Fampridine-SR, to Biogen for US$510 M. Biogen is on a quest to launch the first MS drug in pill form and Acorda may be the ideal partner to achieve that goal with this sustained release formulation of fampridine.